groups, which can react directly with both protein primary amine and sulfhydryl groups.
Antibody monolayers. We used this activation chemistry to investigate whether the molecular packing of the IgG film formed on the water surface is maintained upon deposition on solid supports. IgG molecules are known to form dense and stable monolayers on the water-air interface (3, 4 ) because of the pronounced hydrophobic regions on their solvent-exposed surface. The antibodies were conjugated with the dissociative Eu 3ϩ label to calculate the surface density of the immobilized monolayers. The dependencies of the surface density and area per molecule on the surface pressure within the IgG monolayer are presented in Fig. 1 . Both curves show pronounced inflections in the range of 20 -30 mN/m. Although the curve for the area per molecule (curve b) is not properly a -A isotherm (because the total amount of molecules at the surface is not constant), it is obvious that the orientation of the molecules at the water-air interface changes with the surface pressure. These results demonstrate that antibody monolayers can be transferred from the water-air interface to the solid support and immobilized on it, simultaneously preserving their molecular organization.
Receptor monolayers. We next performed a series of experiments to demonstrate that the antibody monolayer immobilized directly onto the siloxane polymer is comparable by surface density with the IgG layer that was specifically adsorbed onto the receptor sublayer. We first immobilized the Fc-binding receptors on the quartz supports modified with siloxane polymers. We used dissociative Eu 3ϩ label and quartz crystal microbalance technique to measure the surface density of immobilized receptor monolayers. Both methods gave values between 5.8 and 8.9 pmol/cm 2 . Ellipsometric measurements indicated that the thicknesses of the immobilized films were 4 -5 nm (protein A and protein G) and 5-6 nm (protein A/G). These results suggest that the monolayers are densely packed and can prevent the nonspecific interactions of antibodies with the surface. Monoclonal antifluorescein (FITC) antibodies were then adsorbed to the receptor monolayers from the bulk solution, and the surfaces were blocked with bovine serum albumin. Lowmolecular weight protein, adrenodoxin (M r 12 500), conjugated with FITC, was used as an antigen to analyze the binding capacity of the systems. Fluorescent microscopy was applied to collect fluorescence intensity profiles after the binding of FITC-adrenodoxin conjugate to anti-FITC antibodies oriented by receptor monolayers. The area of acquisition was 87 ϫ 87 m 2 . Five images at different places for every sample were acquired by charge-coupled device camera, and the integrated intensity was averaged.
Our main results can be summarized as follows. Monolayers formed from proteins A and G had approximately the same IgG binding ability, and the surface density of adsorbed antibodies was comparable to the IgG monolayer formed at 20 mN/m. The chimeric receptor exhibits some advantage in binding capacity: the antibody film adsorbed onto the sublayer of protein A/G is comparable by density with the IgG monolayer formed at 30 -40 mN/m. The Rapid Analyte Measurement Platform (RAMP™) is an enabling immunodiagnostic platform for quantitative analysis of a wide variety of analytes. Consisting of an immunochromatographic strip in a disposable cartridge and a scanning dual wavelength fluorescence reader, RAMP takes advantage of the inherent simplicity of lateral flow immunochromatography while providing a quantitative measurement of analyte concentration. Using The surface concentrations of antibodies were determined by using dissociative Eu 3ϩ label.
RAMP TM : A Rapid, Quantitative Whole Blood Immu

2-3 drops of whole blood, a test can be completed in 5 min
by placing the blood on the cartridge and placing the cartridge in the fluorescence reader. No training or sample measurement is needed. The system has a low manufacturing cost and a short development time per assay. A patent was issued on the system in the US in May 1998 (1 ) .
The criteria for point-of-care testing (2 ) are affordable cost, a disposable device, and/or minimal maintenance and minimal technical expertise required to perform tests. The sample should be whole blood, low volume, unmetered, and applied directly into the instrument or disposable. There needs to be a simple "goof-proof" strategy for recording collection time and result reporting, a simple strategy for calibration and quality control, data transfer capability compatible with the laboratory or hospital information system and a positive identification and specimen-tracking strategy that eliminates specimen identification error. Results should be rapid and in agreement with accepted "gold standard" tests. RAMP was designed with these requirements in mind.
The RAMP assay has much in common with qualitative immunochromatography assays (3, 4 ) in that it uses the accumulation of a particle population at a location on a membrane strip to indicate the presence of an analyte in the aqueous sample used to transport the particle population along the strip by capillary flow. In general, the particles carry adsorbed or coupled antibodies (Abs) against the analyte. The coated particles (colloidal gold or latex Ͻ1 m in diameter) are dried into a carrier material or directly in the nitrocellulose membrane in the presence of a hydration agent to allow their easy mobilization when wetted by the sample. A few centimeters from the deposited particles, a second Ab against the analyte is dried onto the membrane, creating a "test line". Another Ab directed against the Ab on the latex is applied farther along the strip to form the "control line". The aqueous sample, which can be whole blood, serum, or urine, is contacted with the end of the strip and allowed to wick along it, hydrating the particle population and carrying it along in the capillary flow. As the particles move along the strip, Abs bind the antigen (Ag), with the amount bound depending on the Ag concentration. When the particles reach the test line, some fraction of the population is arrested by the membrane-associated Abs capturing particle-Ag complexes. When the remainder of the population reaches the control line, an additional fraction is arrested, regardless of the presence of bound Ag, indicating that the test was completed successfully. The visible presence of particles at one or both lines constitutes the transduction of the immune recognition reaction and indicates a positive or negative result.
RAMP assays differ from the qualitative assays in that they utilize two classes of particles in every assay: the test particle and an internal standard particle (see Fig. 1A ). Both particles are polystyrene from the same manufacturing batch and thus have the same size and surface properties. Each particle population is labeled internally with a distinct fluorescent dye. The test particle population typically carries a covalently coupled monoclonal antibody against the analyte, whereas the internal standard particle carries an uninvolved covalently coupled monoclonal antibody at the same surface concentration and of the same isotype as the test Ab. In all respects except the actual polypeptide sequence of the Ab, the two populations of particles are identical.
An obstacle to overcome in any immunochromatographic assay is the variability observed from strip to strip at the same analyte concentration attributable to variations in membrane properties, component aging, humidity effects, variable release of particles by the sample, or particle aggregation constraints. The internal standard particle population is used to overcome this variability. The two particle populations are mixed before being dried onto the membrane. When the sample is applied to the membrane strip, typically through a sample pad, which may, for example, allow separation of blood cells from plasma, the two particle populations are released equally and migrate down the strip with the sample. In a "sandwich" assay, a polyclonal antibody against the analyte is immobilized at the test line as described above for the qualitative assay. At a second, internal standard line, an anti-mouse IgG antibody arrests a fraction of both the remaining test and the internal standard particles. The RAMP reader scans the strip and measures the fluorescence intensity of each dye at the test line and internal standard line, from which it calculates the concentration of each particle at each location. The internal standard particles are subject to the same nonspecific interfering reactions as the test particles; therefore, the number of internal standard particles arrested at the internal standard line provides a measure of the fraction of the particles that have successfully reached the end of the strip and are able to participate in an immune reaction. Thus, the ratio of the concentrations of test to internal standard particle provides a measure of analyte concentration that is virtually independent of interfering factors. This ratio is therefore referred to a calibration curve to obtain the analyte concentration.
In a serum assay for myoglobin, the reader-based noise corresponds to a concentration of ϳ0.3 pg/L. Typical test detection limits were near 1.0 pg/L, and the CVs were 5-15% (range) for sera with added myoglobin. Assay performance is independent of sample volume and does not require a metered amount of sample. The data in Fig.  1B show a typical calibration curve for myoglobin. The error bars represent 1 SD calculated on 4 separate days (over a period of 36 days) with five points per concentration on each day. The mean of the CVs for the calibrators was 13%. Fast point-of-care testing of metabolite concentrations has become more common in critical care analysis (1) (2) (3) . We developed an integrated biosensor cassette for the determination of glucose, lactate, and urea in microsamples of undiluted whole blood or plasma. The biosensor cassette requires no maintenance and can be used for 1 week or 500 samples after insertion into an AVL OMNI ® blood gas and electrolyte instrument. The linear analytical ranges of these sensors include the physiological ranges and most of the pathological ranges, e.g., glucose up to 40 mmol/L, lactate up to 20 mmol/L, and urea up to 40 mmol/L. This integrated planar solid state sensor (38 ϫ 20 mm) is produced using thick-film technology, allowing high reproducibility at very competitive manufacturing costs. The sensor cassette consists of 12 electrode spots (each 1.2 mm in diameter); 9 spots are used for glucose and lactate, and 3 are used for urea. The total fill volume of a cassette is 44 L, including 6 L for an external maintenance-free reference electrode for the potentiometric urea sensor system. The integrated biosensor is thermostated in the instrument at 25°C to avoid interference by varying sample temperatures. Results from a whole blood or plasma sample can be obtained within 90 s after sample application. A schematic of the planar sensor is shown in Fig. 1 .
The amperometric three-electrode glucose sensor, including working, counter, and reference electrodes, is based on the glucose oxidase method using hydrogen peroxide detection with electrochemical recycling of the oxygen, thus making the sensor essentially free from interference from the oxygen content of the sample. The lactate sensor is constructed identically but with lactate oxidase immobilized rather than glucose oxidase. To avoid interference problems for both sensors, an amperometric interference compensation electrode is used, which compensates for the electrochemical interference of substances such acetaminophen (paracetamol), uric acid, and ascorbic acid. This sensor uses an inactive immobilized protein rather than glucose oxidase. All three amperometric sensors are calibrated with acetaminophen to achieve perfect correction of interference. Acetaminophen is a good model substance for other exogenous and endogenous interfering substances. [For further details, see Ref. (4 ) .] The potentiometric sensor for urea determinations is based on an ammonium ion-selective electrode (ISE) based on nonactin with immobilized urease to convert urea to bicarbonate and ammonium ions. To avoid interference from native ammonia in the sample, an additional ammonium ISE is used as well as a potassium ISE based on the ionophore valinomycin to compensate for interference from potassium ions at the ammonium sensors. Because the detection principle is via ammonium ISE and the ammonium/ammonia equilibrium is pH dependent, the system will give falsely low results at pH Ͼ8.0 and falsely high results at pH Ͻ6.8. (e.g., a sample with 9.0 mmol/L urea will typically read 8.4 mmol/L at pH 8.0 and 9.8 mmol/L at pH 6.8). However, these numbers further depend on the buffer capacity of the sample (5 ). The enzymes of this integrated biosensor are immobilized via a novel immobilization procedure based on acrylate prepolymers (6 ).
The sensors are calibrated automatically in the reference interval every hour and in the high pathological Fig. 1 . Schematic overview of the planar biosensor, including sensor spots and conductive tracks.
The urea system consists of a urea sensor (12), a potassium ISE (11), and an ammonium ISE (10). The glucose sensor consists of working (8), counter (9), and reference (7) electrodes; the lactate system is designed similarly, with electrodes 4 -6 as the reference, working, and counter electrodes, respectively. The interference-compensating electrode is located in spots 1-3.
